Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Supports Russell Thomas’ Research at the Hamner Institutes for Health Sciences

Published: Thursday, December 08, 2011
Last Updated: Thursday, December 08, 2011
Bookmark and Share
Russell supported for his work developing methods to predict drug-induced liver injury.

Agilent Technologies Inc. and the Agilent Technologies Foundation have announced that Russell S. Thomas, Ph.D., of the Hamner Institutes for Health Sciences has been selected for an Agilent Thought Leader Award to support his work developing methods to predict drug-induced liver injury.

The award includes funding from the Agilent Technologies Foundation as well as instrumentation from the company, including a 6460 triple quadrupole LC/MS and an Agilent microarray scanner.

Dr. Thomas is director of the Institute for Chemical Safety Sciences at the Hamner, where researchers are applying a systems biology approach in an effort to predict drug-induced liver injury.

This includes integration of data from transcriptomics, metabolomics, and genome-wide association studies.

Drug-induced liver injury is a primary reason regulators prohibit drugs or pull them off the market. One of the goals of Dr. Thomas’ work is to eventually be able to identify patients with genetic susceptibility to liver damage from certain drugs. This could reduce injuries and even allow some previously banned drugs to be reintroduced.

“Drug-induced liver injury is a major problem in the development of safe and effective therapeutics,” said Dr. Thomas.

Dr. Thomas continued, “Current analyses of the genome sequence data of patients that have experienced drug-induced liver injury have failed to identify any susceptibility factors that are common across multiple drugs. I am grateful to receive the Agilent Thought Leader Award as an acknowledgment of the importance of the work we are conducting at the Hamner Institutes. The award will allow us to evaluate whether these susceptibility factors can be identified when the drugs are grouped based on the signaling pathways they activate in the liver and ultimately predict which patients may be at risk.”

“The promise of personalized medicine is getting closer every day, and this is why we appreciate the opportunity to help make a real difference by supporting work like Dr. Thomas’,” said Gustavo Salem, vice president and general manager of Agilent’s Biological Systems Division.

Salem continued, “We’ve been strong proponents of an integrated biology approach to solving important health problems for quite some time, and this research at the Hamner aligns well with Agilent’s goals.”

The Agilent Thought Leader Program promotes fundamental advances in the life sciences by contributing financial support, products and expertise to the research of thought leaders.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Completes Acquisition of Seahorse Bioscience
Agilent has completed the acquisition of Seahorse Bioscience, a leader in providing instruments and assay kits for measuring cell metabolism and bioenergetics.
Tuesday, November 03, 2015
Agilent Announces Opening of Life Science Research Center
Facility designed to advance multi-omics research.
Thursday, September 24, 2015
Agilent to Acquire Seahorse Bioscience
Acquisition complements Agilent’s market-leading separations and mass spectrometry solutions, expands pharma offerings.
Thursday, September 10, 2015
Agilent to Focus on "Powerful Partnerships, Inspiring Results" at ASMS 2015
Company to introduce solutions enabling new standards in mass spectrometry, lab productivity.
Friday, May 29, 2015
Agilent, Baylor Open Mass Spec Center of Excellence
The new facility aims to boost metabolomics research at Baylor College of Medicine.
Friday, December 05, 2014
Agilent Thought Leader Award Supports Metabolic Research
Princeton team developing LC/MS methods, bioinformatics tools for discovery of metabolic regulatory mechanisms.
Tuesday, April 22, 2014
Agilent to Host Young Scientist Forums in Asia Pacific
Events provide platform for rising talents in Australia, Singapore to exchange ideas with leading scientific scholars.
Wednesday, March 26, 2014
Agilent, CambTEK Announce LC Sample Prep Agreement
Companies announce agreement to co-market CambTEK's RES automated sample preparation technology with an assortment of Agilent's instruments and software.
Wednesday, February 26, 2014
Agilent Awards Grant for Translational Research in Cardiometabolic Disease
Dr. Christopher Newgard's team at Duke University use Agilent platforms to better understand disease mechanisms.
Thursday, January 16, 2014
Agilent Thought Leader Award Supports Dr. Junying Yuan, Chinese Academy of Sciences
Integrated biological research is accelerating drug development for neurodegenerative diseases.
Wednesday, December 11, 2013
Agilent Reports Fourth-Quarter Results
Agilent Technologies reported orders up 4 percent over one year ago to $1.83 billion with revenues of $1.72 billion, down 3 percent compared with one year ago.
Monday, November 18, 2013
Agilent Recognized as 2013 Laboratory Analytical Instrumentation Company of the Year in China
The company ranked highest in industry for leadership, growth, innovation and customer service by Frost & Sullivan.
Tuesday, August 20, 2013
Agilent and SRI International Sign Licensing Agreement
Agilents’ new pathway Architect software to include SRI International’s BioCyc Pathway database collection.
Wednesday, April 17, 2013
Agilent and Spain’s Centre for Omic Sciences to Collaborate
Both Companies collaborate on integrated systems biology research, establish centre of excellence.
Tuesday, March 05, 2013
Agilent Technologies Thought Leader Award Supports Translational Research Program
The award will support Dr DePinho's research into metabolic reprogramming in the earliest stages of cancer.
Monday, March 04, 2013
Scientific News
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
A Metabolic Twist that Drives Cancer Survival
A novel metabolic pathway that helps cancer cells thrive in conditions that are lethal to normal cells has been identified.
Liver-On-Chip Tracks Dynamics of Cellular Function
Hebrew University’s liver-on-chip platform is uniquely able to monitor metabolic changes indicating mitochondrial damage occurring at drug concentrations previously regarded as safe.
Living Off the Fat of the Land
Do cancer cells synthesize the parts for new cells or scavenge them from the environment?
Liver Disease, Obesity Linked
Kanazawa University researchers find similarities in the impeded signalling between central insulin activity and glucose production in the liver for both obese mice and mice that have had the vagus nerve removed.
Decoding Ties Between Vascular Disease, Alzheimer’s
NIH consortium uses big data, team science to uncover complex interplay of factors.
Gene Identified that May Worsen Cancer Outcome
Some patients with breast cancer, lung cancer and leukaemia seem to fare poorly after treatment because of the effects of a particular gene, a new study finds.
‘Big Data’ Drills Down Into Metabolic Details
Rice University bioengineers introduce efficient way to analyze, compare tissue-specific pathways.
New Approach to Curbing Cancer Cell Growth
Using a new approach, scientists at The Scripps Research Institute (TSRI) and collaborating institutions have discovered a novel drug candidate that could be used to treat certain types of breast cancer, lung cancer and melanoma.
New Drug Delivery Method for Pancreatic Cancer
UCLA researchers use nanoparticles to send chemotherapy drug directly to the tumor site, reducing damage to healthy tissues.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!